Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-107788
Filing Date
2025-11-06
Accepted
2025-11-06 16:31:37
Documents
67
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20250930x10q.htm   iXBRL 10-Q 1975762
2 EX-10.1 acrs-20250930xex10d1.htm EX-10.1 107040
3 EX-31.1 acrs-20250930xex31d1.htm EX-31.1 15498
4 EX-31.2 acrs-20250930xex31d2.htm EX-31.2 15563
5 EX-32.1 acrs-20250930xex32d1.htm EX-32.1 9434
  Complete submission text file 0001104659-25-107788.txt   8565298

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20250930.xsd EX-101.SCH 44401
7 EX-101.CAL acrs-20250930_cal.xml EX-101.CAL 44079
8 EX-101.DEF acrs-20250930_def.xml EX-101.DEF 183288
9 EX-101.LAB acrs-20250930_lab.xml EX-101.LAB 443885
10 EX-101.PRE acrs-20250930_pre.xml EX-101.PRE 302726
70 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20250930x10q_htm.xml XML 1797237
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 251458978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)